Asset Purchase Agreement with Destiny Pharma

AI SummaryClose X

EMV Capital's subsidiary, Moirai Acquisitions Limited, has entered an asset purchase agreement to acquire assets related to Destiny Pharma's XF drug platform for up to £2,475,000. The consideration includes an initial cash payment of £475,000 and deferred consideration of up to £2 million, payable upon achieving specific milestones. These milestones include £600,000 upon launching a US FDA Phase 3 clinical trial, £900,000 upon receiving US regulatory approval, and up to £500,000 upon receiving a potential milestone fee. The initial consideration is funded by a three-year term loan. Additionally, an equity fundraising round aims to raise up to £725,000 for working capital. Following this, approximately £1.86 million will be added to the Group's assets under management.

Disclaimer*

Companies

Emv Capital (EMVC)
UK 100

Latest directors dealings